Sera Prognostics (NASDAQ:SERA) Stock Rating Upgraded by Wall Street Zen

Sera Prognostics (NASDAQ:SERA) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sera Prognostics in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Sera Prognostics currently has an average rating of “Sell”.

Sera Prognostics Trading Up 9.0%

Shares of SERA stock opened at $3.65 on Friday. Sera Prognostics has a 12-month low of $1.37 and a 12-month high of $9.13. The stock’s 50-day moving average price is $3.09 and its 200-day moving average price is $2.70. The stock has a market capitalization of $137.51 million, a price-to-earnings ratio of -4.29 and a beta of 0.97.

Sera Prognostics (NASDAQ:SERA) last issued its earnings results on Wednesday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.05. Sera Prognostics had a negative return on equity of 45.86% and a negative net margin of 30,306.48%.The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.05 million. As a group, research analysts predict that Sera Prognostics will post -0.96 EPS for the current fiscal year.

Insider Transactions at Sera Prognostics

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 21,158 shares of the company’s stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $3.15, for a total transaction of $66,647.70. Following the sale, the chief executive officer directly owned 811,136 shares in the company, valued at $2,555,078.40. This represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders sold 50,631 shares of company stock worth $153,604 in the last quarter. Corporate insiders own 13.50% of the company’s stock.

Institutional Investors Weigh In On Sera Prognostics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Baker BROS. Advisors LP raised its position in Sera Prognostics by 1.2% during the first quarter. Baker BROS. Advisors LP now owns 5,498,170 shares of the company’s stock valued at $20,233,000 after purchasing an additional 63,771 shares during the period. Aberdeen Group plc raised its position in Sera Prognostics by 79.6% during the second quarter. Aberdeen Group plc now owns 2,227,367 shares of the company’s stock valued at $6,170,000 after purchasing an additional 987,367 shares during the period. AWM Investment Company Inc. raised its position in Sera Prognostics by 48.1% during the first quarter. AWM Investment Company Inc. now owns 866,837 shares of the company’s stock valued at $3,190,000 after purchasing an additional 281,703 shares during the period. Captrust Financial Advisors grew its stake in shares of Sera Prognostics by 20.0% during the second quarter. Captrust Financial Advisors now owns 602,277 shares of the company’s stock valued at $1,668,000 after buying an additional 100,366 shares during the last quarter. Finally, Sanders Morris Harris LLC grew its stake in shares of Sera Prognostics by 179.8% during the second quarter. Sanders Morris Harris LLC now owns 263,600 shares of the company’s stock valued at $730,000 after buying an additional 169,400 shares during the last quarter. 54.64% of the stock is currently owned by hedge funds and other institutional investors.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.